Form 4: BIODESIX CFO Sells Shares for Tax After RSU Vesting

BIODESIX Inc.'s CFO, Robin Harper Cowie, reported the acquisition of common stock through RSU vesting and a subsequent sale to cover tax obligations.

Summary

• Robin Harper Cowie, CFO, Secretary & Treasurer of BIODESIX INC (BDSX), reported transactions involving company common stock.
• On February 9, 2026, Cowie acquired 2,584 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• These RSUs included 157 units that vested from a series of sixteen quarterly installments starting February 8, 2022, and 2,427 units that vested from a series of four annual installments starting February 8, 2023.
• On February 10, 2026, Cowie sold 941 shares of common stock at a weighted average price of $10.0841 per share.
• This sale was automatically executed to cover tax obligations arising from the RSU vesting.
• Following these transactions, Cowie beneficially owns 15,297 shares of BIODESIX common stock.
• The reported share numbers reflect adjustments due to a one-for-twenty reverse stock split effective September 15, 2025.
• Cowie still holds 2,426 Restricted Stock Units as derivative securities after the reported vesting event.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports routine executive compensation events (RSU vesting and tax-related share sale) that do not indicate any significant positive or negative operational or financial developments for the company.

Positives

• The vesting of 2,584 Restricted Stock Units indicates continued compensation and retention of a key executive.
• The executive's beneficial ownership of 15,297 shares demonstrates ongoing alignment with shareholder interests.

Negatives

• A portion of the newly vested shares (941 shares) was sold, which, while for tax purposes, represents a reduction in direct holdings.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that routine Form 4 filings, such as this one detailing RSU vesting and subsequent tax-related sales by an executive, are common occurrences in publicly traded companies. They reflect standard executive compensation practices and do not typically indicate a shift in broader industry trends or competitive landscape. The reverse stock split mentioned is a company-specific event that can impact share price and liquidity, but its mention here is purely for context of the share numbers.

Comparison to Industry Standards

• Routine RSU vesting and subsequent 'sell-to-cover' tax transactions by executives are standard practice across industries, including biotechnology and diagnostics, where BIODESIX operates.
• Companies like Guardant Health (GH) or Exact Sciences (EXAS) also frequently report similar executive compensation-related transactions.
• The sale of 941 shares to cover taxes on a vesting of 2,584 shares is a typical proportion, reflecting standard income tax rates on equity compensation. This transaction does not deviate from common executive compensation and tax management practices observed in comparable companies.

Related Party Transactions

• The RSU vesting and subsequent tax-related sale are part of the reporting person's compensation package as an officer of the issuer, which is a standard employment-related transaction rather than an unusual related party dealing.

Stakeholder Impact

• Shareholders: The transaction is a routine executive compensation event and is unlikely to have a significant direct impact on shareholders, beyond the minor dilution from RSU vesting (already accounted for in compensation plans) and the executive's continued alignment through share ownership.
• Employees: No direct impact on employees is indicated.
• Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, specifically the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations. Such transactions are standard and do not provide new fundamental information that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, as the filing does not present compelling reasons to buy or sell based solely on these reported events.

Keywords

BIODESIX, BDSX, Form 4, Insider Trading, Robin Harper Cowie, CFO, Restricted Stock Units, RSU vesting, stock sale, tax obligations, corporate governance